DR REDDYS LABORATORIES LTD
No SEC Form 4 filings for $RDY in the last 30 days.
See all $RDY insider activity →Dr Reddy's Laboratories' US subsidiary received a $32,350 IRS penalty for misclassifying its fiscal year. The company stated this has no material financial impact. Separately, the USFDA issued two observations after an assessment of its Mexico API facility. Shares closed 2.51% lower on October 1, 2026.
Dr Reddy's Laboratories has signed a royalty-free licensing agreement with Gilead Sciences to manufacture and supply investigational once-yearly lenacapavir for HIV prevention in 120 countries. The drug is currently in Phase 3 clinical trials and not yet approved. This expands their existing partnership for twice-yearly lenacapavir, which is approved by USFDA, EMA, and recommended by WHO. The agreement aims to support manufacturing and supply planning in high-incidence, low- and lower-middle-inc
GLP-1 drug sales in Canada are on track to reach $4.8 billion in 2026, up from $3.9 billion in 2025. Novo Nordisk's Ozempic led with $1.49 billion in sales, followed by Wegovy, Mounjaro, and Zepbound. Generic versions from Apotex and Dr. Reddy's had modest sales. IQVIA Canada provided the data.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RDY (DR REDDYS LABORATORIES LTD). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent RDY coverage spans regulation, sector analysis and financial news.
Minor penalty with no material impact, but shares already down 2.5% on the news.
Potential revenue upside from expanded market reach and manufacturing volume.
Minor impact but signals entry into Canadian GLP‑1 market.
The Form 483 observations create near-term compliance and operational risk for RDY’s US formulations manufacturing, potentially affecting timelines and remediation costs.
A favorable USFDA GMP outcome reduces near-term regulatory overhang for RDY’s API manufacturing, though VAI implies some voluntary remediation may still be expected.
AlphAI scores every news story that mentions RDY with an AI model for sentiment and relevance, and aggregates insider trades from DR REDDYS LABORATORIES LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Dr Reddy's Laboratories' US subsidiary received a $32,350 IRS penalty for misclassifying its fiscal year. The company stated this has no material financial impact. Separately, the USFDA issued two observations after an assessment of its Mexico API facility. Shares closed 2.51% lower on October 1, 2026.
1 min readDr Reddy's Laboratories has signed a royalty-free licensing agreement with Gilead Sciences to manufacture and supply investigational once-yearly lenacapavir for HIV prevention in 120 countries. The drug is currently in Phase 3 clinical trials and not yet approved. This expands their existing partnership for twice-yearly lenacapavir, which is approved by USFDA, EMA, and recommended by WHO. The agreement aims to support manufacturing and supply planning in high-incidence, low- and lower-middle-inc
2 min readGLP-1 drug sales in Canada are on track to reach $4.8 billion in 2026, up from $3.9 billion in 2025. Novo Nordisk's Ozempic led with $1.49 billion in sales, followed by Wegovy, Mounjaro, and Zepbound. Generic versions from Apotex and Dr. Reddy's had modest sales. IQVIA Canada provided the data.
2 min readDr. Reddy’s Laboratories said the US FDA completed a GMP inspection of its Bachupally, Hyderabad formulations facility (FTO-3) from Aug 6 to Aug 14, 2026. The company received a Form 483 listing four observations and plans to address them within the required timeline.
2 min readDr. Reddy’s Laboratories said the US FDA concluded a GMP inspection of its API manufacturing facility in Mirfield, UK. The agency classified the outcome as “Voluntary Action Indicated (VAI)” and closed the inspection under 21 CFR 20.64(d)(3). The update is intended for stakeholder records.
2 min readDr. Reddy’s Laboratories said the US FDA inspected its Hyderabad formulations facility FTO-3 (Bachupally) from Aug 6-14, 2026 and issued a Form 483 listing four observations. The company must prepare and implement a remediation plan within the US FDA’s timeline. Investors may watch for updates on corrective actions and closure.
2 min readDr. Reddy’s Laboratories Limited said CEO, API and Services Deepak Sapra will resign and leave the company’s senior management effective Nov. 12, 2026, after providing transition support until that date. The firm filed the disclosure under SEBI Regulation 30, citing Sapra’s plan to pursue opportunities outside the company.
2 min readTrump proposed tariffs on imported generic medicines, with zero duties for two years from Aug 1, 2026, then 100% from Aug 1, 2028, and 200% from Aug 1, 2029, aiming to spur US manufacturing. Executives said building capacity would take at least five years. Indian pharma stocks fell on the BSE; Lupin -4.2%, Aurobindo -2%, Dr Reddy’s -2%.
6 min readTrump threatened up to 200% tariffs on imported generic drugs after a two-year transition. An analysis of annual reports and earnings calls says Indian drugmakers are increasing R&D, launches and capacity rather than wholesale US relocation. Dr Reddy’s CEO said moving facilities in two years is impractical. Dr Reddy’s and Cipla detail US launch manufacturing; Lupin, Zydus, Biocon, Torrent and Divi outline targeted investments and risk responses.
7 min readSignature Global said it awarded ₹920 crore construction contracts for its Sarvam at DXP Estate in Gurugram, with KEC International and NCC building 11 towers and 1,798 units. IndusInd Bank received RBI approval to form a wholly-owned stockbroking subsidiary. Novartis India will end its Dr. Reddy’s distribution deal from Sep 30, 2026. Emcure Pharma got USFDA closure for its Sanand facility, AstraZeneca Pharma India gained approval for Enhertu. NTPC Green Energy won a battery storage project and
7 min read
